The global postpartum depression management market is poised to register a 3.8% CAGR, capturing a revenue share of US$ 115.1 million in 2022, to reach US$ 173.9 million by 2032.
In pregnancy and childbirth, there is an acute case of clinical depression that is called postpartum depression. It is a very common mood disorder examined specifically in pregnant mothers, though it affects both men and women.
As per a study published in a peer-reviewed journal, 1 out of 7 women who gave birth to a newborn suffered from postpartum depression. After three weeks of giving birth to a newborn, a mother starts feeling the effects of depression.
Postpartum depression management market growth is attributed to various factors that affect postpartum depression rates after pregnancy. These risk factors include hormonal and physical changes, a history of depression and stress, emotional imbalance, and bipolar disorder.
In pregnancy, mental disorders and mood swings are driving growth in the postpartum depression management market. Some of the major symptoms of postpartum depression among women include hopelessness, sadness, learning and memorizing, inability to focus, anxiety and exhaustion, loss of interest in self-care, and appetite problems.
| Report Attribute | Details |
|---|---|
| Postpartum Depression Management Market Value (2022) | US$ 115.1 Million |
| Postpartum Depression Management Market Anticipated Forecast Value (2032) | US$ 173.9 Million |
| Postpartum Depression Management Market Projected Growth Rate (2022 to 2032) | 3.8% |
To achieve better results, getting diagnosed by a doctor is crucial. Antidepressant prescriptions include Bupropion, Amitriptyline, Trimipramine, Fluoxetine, Paroxetine, Fluoxetine, Fluoxetine, Fluoxetine, Fluoxetine, and others. In contrast, counseling involves talk therapy with therapists or psychologists who provide management tips to help combat the conditions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The growing demand for antidepressant drugs and talk therapies by expectant pregnant mothers is projecting the growth of the postpartum depression management market. Therefore, spending on postpartum depression management is increasing over time.
The postpartum depression management market is growing worldwide as women across the globe are lately experiencing postpartum depression as they find it difficult to cope with new responsibilities. The postpartum depression management market includes various home remedies that involve maintaining healthy lifestyle choices, avoiding isolation, to set realistic expectations.
Based on treatment type, anti-depressants are the most commonly used treatment methods over therapies as anti-depressants provide fast treatment and promising results in less time as compared with psychotherapies.
The anti-depressants treatment segment thus accounts for the largest revenue share in the postpartum depression management market. The segment is anticipated to follow the same trend in the postpartum depression management market over the next few years. As a result, women prefer it over psychotherapies to achieve faster results.
Some of the key factors driving the growth of the postpartum depression management market include the rise in risk factors associated with postpartum depression. These include the growing preference of women for the treatment of postpartum depression.
Women have become more aware of postpartum depression management and are more inclined to seek early treatment and therapies, which is further driving the global market for postpartum depression management.
It is expected that postpartum depression management market growth will be constrained by negligence and unacceptance of the condition, along with an inability to detect depression.
The demand for postpartum depression management has increased in the North American region. North America is anticipated to control a postpartum depression management market share of 37.5% in 2022.
In the last decade, North America has held the largest revenue share in the global postpartum depression management market on account of rising awareness among women regarding postpartum depression. It also enhanced decision-making by women with high educational attainment and easy availability of psychotherapy sessions with specialized doctors.
Europe's Postpartum Depression Management is predicted to experience significant growth and hold a market share of 29% in 2022. Mental health awareness is increasing among individuals and major companies are investing in countries in this region, which is driving revenues in the Europe postpartum depression market.
The market for postpartum depression in Europe is expected to be driven by an increasing number of initiatives to treat postpartum depression through telemedicine virtual support over calls and online counseling, as well as an increasing number of support groups and mental health communities for mothers.
Principal Consultant
The start-up ecosystem in the postpartum depression management market is clouded by several pharmaceutical companies, including Marinus Pharma and others, who are actively developing therapies to grow the postpartum depression management market share. In addition, they manufacture novel therapies to transform the treatment paradigm of the postpartum depression management market.
Sage Therapeutics and Marinus Pharmaceuticals are two major players developing therapies for postpartum depression (PPD). There will be a significant impact on the postpartum depression (PPD) market from the launch of new therapies such as SAGE-217 and Ganaxolone.
The postpartum depression management market is consolidated with a presence of a few strong players from around the globe. Some of the key players present in the global postpartum depression management market are Sage Therapeutics Inc., Cipla Limited, Sun Pharmaceutical Industries Ltd., Anikem Laboratories, Intas Pharmaceuticals Ltd., Mylan N.V., Sumika Fine Chemicals Co Ltd., and others.
emerging trends in the postpartum depression management market are brought about as a result of the major players' adoption of several growth strategies, including product launches, acquisitions, and collaborations.
Some of the recent developments in the Postpartum Depression Management market are as follows:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 3.8% from 2022 to 2032 |
| Base Year for Estimation | 2022 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The postpartum depression management market is likely to account for US$ 173.9 million by 2032.
North America is likely to hold a postpartum depression management market share of 37.5% in 2022.
The global postpartum depression management market is set to advance at a CAGR of 3.8% from 2022 to 2032.
The postpartum depression management market is projected to grow to US$ 115.1 million in 2022.
1. Executive Summary | Postpartum Depression Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2022 to 2032 5.3.1. Anti-Depressant Drugs 5.3.2. New Anti-Depressant Drugs 5.3.3. SAGE-547 5.3.4. Bupropion 5.3.5. Escitalopram 5.3.6. Fluoxetine 5.3.7. Paroxetine 5.3.8. Sertraline 5.3.9. Old Anti-Depressant Drugs 5.3.10. Amitriptyline 5.3.11. Desipramine 5.3.12. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Treatment, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Drug Stores 6.3.4. E-commerce 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 8.2.1. By Country 8.2.1.1. United States of America 8.2.1.2. Canada 8.2.2. By Treatment 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. India 11.2.1.5. Malaysia 11.2.1.6. Singapore 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of Asia-Pacific 11.2.2. By Treatment 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of Middle East and Africa 12.2.2. By Treatment 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. United States of America 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2021 13.1.2.1. By Treatment 13.1.2.2. By Distribution Channel 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2021 13.2.2.1. By Treatment 13.2.2.2. By Distribution Channel 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2021 13.3.2.1. By Treatment 13.3.2.2. By Distribution Channel 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2021 13.4.2.1. By Treatment 13.4.2.2. By Distribution Channel 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2021 13.5.2.1. By Treatment 13.5.2.2. By Distribution Channel 13.6. United Kingdom 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2021 13.6.2.1. By Treatment 13.6.2.2. By Distribution Channel 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2021 13.7.2.1. By Treatment 13.7.2.2. By Distribution Channel 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2021 13.8.2.1. By Treatment 13.8.2.2. By Distribution Channel 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2021 13.9.2.1. By Treatment 13.9.2.2. By Distribution Channel 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2021 13.10.2.1. By Treatment 13.10.2.2. By Distribution Channel 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2021 13.11.2.1. By Treatment 13.11.2.2. By Distribution Channel 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2021 13.12.2.1. By Treatment 13.12.2.2. By Distribution Channel 13.13. Malaysia 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2021 13.13.2.1. By Treatment 13.13.2.2. By Distribution Channel 13.14. Singapore 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2021 13.14.2.1. By Treatment 13.14.2.2. By Distribution Channel 13.15. Australia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2021 13.15.2.1. By Treatment 13.15.2.2. By Distribution Channel 13.16. New Zealand 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2021 13.16.2.1. By Treatment 13.16.2.2. By Distribution Channel 13.17. GCC Countries 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2021 13.17.2.1. By Treatment 13.17.2.2. By Distribution Channel 13.18. South Africa 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2021 13.18.2.1. By Treatment 13.18.2.2. By Distribution Channel 13.19. Israel 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2021 13.19.2.1. By Treatment 13.19.2.2. By Distribution Channel 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Treatment 14.3.3. By Distribution Channel 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. SAGE Therapeutics Inc. 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Cipla Limited 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Sun Pharmaceutical Industries Ltd. 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Anikem Laboratories 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Intas Pharmaceuticals Ltd. 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Mylan N.V. 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Sumika Fine Chemicals Co Ltd. 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Aurobindo Pharma 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Lupin 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Accord Healthcare 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Postpartum Depression Management Market
